- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04314401
National Cancer Institute "Cancer Moonshot Biobank"
Cancer Moonshot Biobank Research Protocol
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Studieoversigt
Status
Betingelser
- Ondartet fast neoplasma
- Melanom
- Akut myeloid leukæmi
- Myelomatose
- Anatomisk fase III brystkræft AJCC v8
- Anatomisk fase IV brystkræft AJCC v8
- Æggelederkarcinom
- Gastrisk karcinom
- Ikke-småcellet lungekarcinom
- Stadie III lungekræft AJCC v8
- Stadie IV lungekræft AJCC v8
- Metastatisk prostatakarcinom
- Ovariekarcinom
- Esophageal carcinom
- Invasivt brystkarcinom
- Stadie IVB prostatakræft AJCC v8
- Klinisk fase IV gastrisk cancer AJCC v8
- Klinisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Triple-negativt brystkarcinom
- Fase IV kolorektal cancer AJCC v8
- Primært peritonealt karcinom
- Klinisk trin IV Esophageal Adenocarcinom AJCC v8
- Ovarial højgradigt serøst adenokarcinom
- Fase III æggelederkræft AJCC v8
- Fase III Kræft i æggestokkene AJCC v8
- Fase IV æggelederkræft AJCC v8
- Fase IV Kræft i æggestokkene AJCC v8
- Hormonreceptor-positivt brystkarcinom
- Lunge småcellet karcinom
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To support current and future investigations into drug resistance and sensitivity and other National Cancer Institute (NCI)-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCI Community Oncology Research Program (NCORP) sites and other National Clinical Trials Network (NCTN) sites.
SECONDARY OBJECTIVES:
I. To provide a service of value to study participants and their medical providers through the performance of molecular profiling assays on tumor samples in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory and reporting of results to physicians and patients that they may opt to use in clinical management, including analysis of data for acquired resistance mechanisms.
II. To enable the development of patient-derived models such as cell lines and xenografts for cancer researchers through the provision of biospecimens from up to 20% of study participants to the NCI's Patient Derived Models Repository (PDMR), a national resource available to investigators.
III. To develop and implement robust approaches in patient and provider engagement to improve understanding of biobanking and its relationship to cancer research and increase representation of minority and underserved study participants in cancer research.
IV. To develop increased capabilities in United States (U.S.) community hospitals and clinics for contribution to cancer research through biobanking activities.
V. To enable secondary research generated from the project through deposition of data in public repositories such as Cancer Research Data Commons (CRDC), The Cancer Imaging Archive (TCIA) and database of Genotypes and Phenotypes (dbGaP) and other potential NCI databases, including clinical, radiology and pathology data with an emphasis on treatment response and outcome data.
VI. To provide residual biospecimens and associated data from the project to the cancer research community.
OUTLINE:
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo computed tomography (CT), positron emission tomography (PET)/CT and/or magnetic resonance imaging (MRI) throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Daphne, Alabama, Forenede Stater, 36526
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, Forenede Stater, 36532
- Thomas Hospital
-
Mobile, Alabama, Forenede Stater, 36607
- Mobile Infirmary Medical Center
-
Saraland, Alabama, Forenede Stater, 36571
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Kingman, Arizona, Forenede Stater, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Fort Smith, Arkansas, Forenede Stater, 72903
- Mercy Hospital Fort Smith
-
-
California
-
Arroyo Grande, California, Forenede Stater, 93420
- PCR Oncology
-
Bakersfield, California, Forenede Stater, 93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Loma Linda, California, Forenede Stater, 92357
- Veterans Affairs Loma Linda Healthcare System
-
Salinas, California, Forenede Stater, 93901
- Salinas Valley Memorial
-
-
Colorado
-
Brighton, Colorado, Forenede Stater, 80601
- Intermountain Health Platte Valley Hospital
-
Denver, Colorado, Forenede Stater, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Golden, Colorado, Forenede Stater, 80401
- Lutheran Hospital - Cancer Centers of Colorado
-
Grand Junction, Colorado, Forenede Stater, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Lafayette, Colorado, Forenede Stater, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06102
- Hartford Hospital
-
-
Delaware
-
Dover, Delaware, Forenede Stater, 19901
- Bayhealth Hospital Kent Campus
-
Milford, Delaware, Forenede Stater, 19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33486
- Boca Raton Regional Hospital
-
Deerfield Beach, Florida, Forenede Stater, 33064
- Broward Health North
-
Fort Lauderdale, Florida, Forenede Stater, 33316
- Broward Health Medical Center
-
Tampa, Florida, Forenede Stater, 33606
- Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30342
- Northside Hospital
-
Savannah, Georgia, Forenede Stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Illinois
-
Bloomington, Illinois, Forenede Stater, 61704
- Illinois CancerCare-Bloomington
-
Chicago, Illinois, Forenede Stater, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Forenede Stater, 60625
- Swedish Covenant Hospital
-
Danville, Illinois, Forenede Stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forenede Stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forenede Stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston, Illinois, Forenede Stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Forenede Stater, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, Forenede Stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Forenede Stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon, Illinois, Forenede Stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Forenede Stater, 62864
- SSM Health Good Samaritan
-
Pekin, Illinois, Forenede Stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forenede Stater, 61615
- Illinois CancerCare-Peoria
-
Urbana, Illinois, Forenede Stater, 61801
- Carle Cancer Center
-
Washington, Illinois, Forenede Stater, 61571
- Illinois CancerCare - Washington
-
-
Iowa
-
Ames, Iowa, Forenede Stater, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Forenede Stater, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Cedar Rapids, Iowa, Forenede Stater, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, Forenede Stater, 52402
- Physicians' Clinic of Iowa PC
-
Des Moines, Iowa, Forenede Stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forenede Stater, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, Forenede Stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70808
- Our Lady of the Lake Physician Group
-
New Orleans, Louisiana, Forenede Stater, 70118
- Children's Hospital New Orleans
-
New Orleans, Louisiana, Forenede Stater, 70112
- University Medical Center New Orleans
-
Shreveport, Louisiana, Forenede Stater, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta, Maine, Forenede Stater, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Forenede Stater, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Forenede Stater, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brunswick, Maine, Forenede Stater, 04011
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Brunswick, Maine, Forenede Stater, 04011
- Mid Coast Hospital
-
Damariscotta, Maine, Forenede Stater, 04543
- MaineHealth LincolnHealth Hospital
-
Farmington, Maine, Forenede Stater, 04938
- MaineHealth Franklin Hospital
-
Lewiston, Maine, Forenede Stater, 04240
- Saint Mary's Regional Medical Center
-
Norway, Maine, Forenede Stater, 04268
- MaineHealth Stephens Hospital
-
Portland, Maine, Forenede Stater, 04102
- Maine Medical Partners Surgical Care
-
Portland, Maine, Forenede Stater, 04102
- MMP Surgical Care Casco Bay
-
Portland, Maine, Forenede Stater, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Forenede Stater, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Forenede Stater, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Forenede Stater, 04074
- Maine Children's Cancer Program
-
Scarborough, Maine, Forenede Stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Forenede Stater, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
South Portland, Maine, Forenede Stater, 04106
- MaineHealth Urology - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Forenede Stater, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Forenede Stater, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Forenede Stater, 48118
- Chelsea Hospital
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Iron Mountain, Michigan, Forenede Stater, 49801
- Dickinson County Healthcare System
-
Livonia, Michigan, Forenede Stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Forenede Stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
-
Missouri
-
Ballwin, Missouri, Forenede Stater, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Joplin, Missouri, Forenede Stater, 64804
- Freeman Health System
-
Joplin, Missouri, Forenede Stater, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Forenede Stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Forenede Stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Forenede Stater, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, Forenede Stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forenede Stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forenede Stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forenede Stater, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Forenede Stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forenede Stater, 63128
- Mercy Hospital South
-
Washington, Missouri, Forenede Stater, 63090
- Mercy Hospital Washington
-
-
Montana
-
Billings, Montana, Forenede Stater, 59102
- Saint Vincent Frontier Cancer Center
-
Butte, Montana, Forenede Stater, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Grand Island, Nebraska, Forenede Stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
-
Nevada
-
Carson City, Nevada, Forenede Stater, 89703
- Carson Tahoe Regional Medical Center
-
Las Vegas, Nevada, Forenede Stater, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forenede Stater, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Forenede Stater, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Forenede Stater, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Forenede Stater, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Forenede Stater, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Forenede Stater, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Hampshire
-
Nashua, New Hampshire, Forenede Stater, 03060
- Saint Joseph Hospital
-
-
New Jersey
-
Morristown, New Jersey, Forenede Stater, 07960
- Morristown Medical Center
-
Newton, New Jersey, Forenede Stater, 07860
- Newton Medical Center
-
Pompton, New Jersey, Forenede Stater, 07444
- Chilton Medical Center
-
Summit, New Jersey, Forenede Stater, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Forenede Stater, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
The Bronx, New York, Forenede Stater, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Forenede Stater, 10467
- Children's Hospital at Montefiore
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Forenede Stater, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Forenede Stater, 27834
- East Carolina University
-
Greenville, North Carolina, Forenede Stater, 27834
- ECU Health Medical Center
-
Kernersville, North Carolina, Forenede Stater, 27284
- Novant Health Cancer Institute - Kernersville
-
Kinston, North Carolina, Forenede Stater, 28501
- ECU Health Oncology Kinston
-
Mount Airy, North Carolina, Forenede Stater, 27030
- Novant Health Cancer Institute - Mount Airy
-
Pinehurst, North Carolina, Forenede Stater, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Thomasville, North Carolina, Forenede Stater, 27360
- Novant Health Cancer Institute - Thomasville
-
Washington, North Carolina, Forenede Stater, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
Winston-Salem, North Carolina, Forenede Stater, 27103
- Novant Health Forsyth Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73120
- Mercy Hospital Oklahoma City
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02908
- Roger Williams Medical Center
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater, 29203
- Prisma Health Richland Hospital
-
Columbia, South Carolina, Forenede Stater, 29220
- Prisma Health Baptist Hospital
-
Gaffney, South Carolina, Forenede Stater, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, Forenede Stater, 29651
- Gibbs Cancer Center-Pelham
-
Spartanburg, South Carolina, Forenede Stater, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Forenede Stater, 29379
- SMC Center for Hematology Oncology Union
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78229
- Audie L Murphy VA Hospital
-
-
Virginia
-
Lynchburg, Virginia, Forenede Stater, 24501
- Centra Alan B Pearson Regional Cancer Center
-
Richmond, Virginia, Forenede Stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Renton, Washington, Forenede Stater, 98055
- Valley Medical Center
-
Yakima, Washington, Forenede Stater, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Huntington, West Virginia, Forenede Stater, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Forenede Stater, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Aurora Saint Luke's Medical Center
-
Minocqua, Wisconsin, Forenede Stater, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Forenede Stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forenede Stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Forenede Stater, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Forenede Stater, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
-
-
-
San Juan, Puerto Rico, 00917
- San Juan Community Oncology Group
-
San Juan, Puerto Rico, 00927
- Centro Comprensivo de Cancer de UPR
-
San Juan, Puerto Rico, 00936
- San Juan City Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients undergoing treatment for cancer types with commercially available therapies.
Beskrivelse
Inclusion Criteria:
-
Is consistent with OR has been diagnosed with one of the following:
-
Colorectal cancer: stage IV
-
Non-small cell or small cell lung cancer: stage III/IV
-
Prostate cancer: metastatic prostate cancer
-
Gastric cancer, not otherwise specified (NOS): stage IV
-
Esophageal cancer, NOS: stage IV
-
Adenocarcinoma of gastroesophageal junction: stage IV
-
High grade serous ovarian cancer: stage III/IV
-
Invasive breast carcinoma: stage III/IV
-
Melanoma: stage III/IV
-
Acute myeloid leukemia
-
Multiple myeloma
-
For the purposes of this study,
- Re-staging is allowed
- Having more than one primary cancer is allowed, if the patient is being treated solely for one of the eligible cancers listed above
-
-
-
Patient should fit in one of the following four clinical scenarios (a-d)
- Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
- Scheduled to begin treatment with a new regimen of standard of care therapy OR
- Currently progressing on a regimen of standard of care therapy OR
- Currently being treated with a regimen standard of care therapy, without evidence of progression
-
Requirements for fresh tissue biospecimen collections at enrollment:
-
For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment
-
For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy
-
For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure
-
For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR
-
The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling
- Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
-
-
-
Requirements for archival tissue:
-
For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE
-
For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED
-
Pre-existing archival material (formalin-fixed, paraffin-embedded [FFPE] block, BM aspirate, or unstained slides) that:
- Contains the cancer type for which the participant is enrolled, and
- Was collected no more than 5 years prior to initiation of therapy, and
- Contains at least a surface area of 5 mm^2 and optimal surface area of 25 mm^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
- Contains at least 10% tumor content. 70% tumor content is optimal, and
- No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
-
-
Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment
- Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
- Blood collection for clinical scenario d must take place within 4 weeks of enrollment, and while patient is on treatment
-
Age 13 or older
-
Any sex
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
-
Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC who are 40 years old or younger at time of collection irrespective of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with BRCA that are either
- Any race/ethnicity with hormone receptor positive (ER+PR+, ER+PR-, or ER-PR+)
- African American with triple negative (ER-PR-HER2-)
-
NCI PDMR INCLUSION CRITERIA: Patients with lung cancer (LCA), prostate cancer (PCA), gastroesophageal cancer (GEC), ovarian cancer (OV), acute myeloid leukemia (AML), multiple myeloma (MML)
Exclusion Criteria:
-
Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial
- For the purposes of this study, past enrollment in clinical trials whereby the patient was randomized and treated with standard-of-care anti-cancer treatment (chemotherapy regimen, surgery and radiation therapy) is allowed
-
Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
-
Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion
-
Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use
-
Factor X inhibitors are permitted
-
Use of anti-platelet drugs are permitted
- Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
-
-
NCI PDMR EXCLUSION CRITERIA: Patients with complete response
-
NCI PDMR EXCLUSION CRITERIA: Patients with invasive fungal infections
-
NCI PDMR EXCLUSION CRITERIA: Patients with active and/or uncontrolled infections or who are still recovering from an infection
- Actively febrile patients with uncertain etiology of febrile episode
- All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
- No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
-
NCI PDMR EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HBV/HCV without documented resolution
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Observational (biospecimen collection, chart review)
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years. |
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Undergo PET/CT
Andre navne:
Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
Andre navne:
Medical charts are reviewed and data is collected
Andre navne:
Undergo paracentesis |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procure, store and distribute longitudinal biospecimens and associated clinical data
Tidsramme: Up to 10 years
|
Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate. |
Up to 10 years
|
|
Percentage of enrolled patients by cancer type and treatment regimen overall
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of minority and underserved study participants accrued
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of minority and underserved study participants accrued
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Pan-cancer gene panel tumor next generation sequencing test
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling is attempted
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling results are generated
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom samples are obtained at each longitudinal timepoint
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Lyndsay N Harris, National Cancer Institute (NCI)
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Karsygdomme
- Hjerte-kar-sygdomme
- Genitale neoplasmer, mandlige
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Kønssygdomme, mandlige
- Prostatasygdomme
- Mandlige urogenitale sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Tarmsygdomme
- Sygdomme i immunsystemet
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Kønssygdomme, kvindelige
- Lungesygdomme
- Hæmatologiske sygdomme
- Neoplasmer i endokrine kirtler
- Neoplasmer i hoved og hals
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Tyktarmssygdomme
- Esophageale sygdomme
- Ovariesygdomme
- Adnexale sygdomme
- Genitale neoplasmer, kvindelige
- Gonadale lidelser
- Hudsygdomme
- Brystsygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Leukæmi, myeloid
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Neuroendokrine tumorer
- Neoplasmer, Plasmacelle
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Hæmoragiske lidelser
- Leukæmi
- Nevi og melanomer
- Neoplasmer i huden
- Æggeledersygdomme
- Brystneoplasmer
- Hud- og bindevævssygdomme
- Hemiske og lymfatiske sygdomme
- Prostatiske neoplasmer
- Neoplasmer i maven
- Lungeneoplasmer
- Kolorektale neoplasmer
- Leukæmi, Myeloid, Akut
- Esophageale neoplasmer
- Ovariale neoplasmer
- Karcinom, ikke-småcellet lunge
- Myelomatose
- Småcellet lungekarcinom
- Melanom
- Tredobbelt negative brystneoplasmer
- Æggelederneoplasmer
- Undersøgelsesteknikker
- Terapeutik
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Punkteringer
- Kirurgiske procedurer, operative
- Kemiteknikker, analytisk
- Spektrumanalyse
- Dræning
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Paracentese
Andre undersøgelses-id-numre
- NCI-2020-00750
- NCI-2020-00750 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 10323 (Anden identifikator: CTEP)
- 10323 (Anden identifikator: Division of Cancer Treatment and Diagnosis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .